Equity Profile

DNLI

Denali Therapeutics Inc.

Health CareBiotechnology$3.1B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Denali Therapeutics Inc. (DNLI) is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth will indicate the demand for Denali's products and its market position.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Denali Therapeutics Inc. (DNLI) is a biotechnology company focused on developing therapies for neurodegenerative diseases. With a market cap of $3 billion, its work is crucial as it addresses significant health challenges in an aging population, particularly in areas like Alzheimer's and Parkinson's diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1 2026, Denali reported an EPS of -$0.69, slightly beating expectations. However, the stock fell 3.43% the following day, indicating market disappointment despite the beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Denali's upcoming earnings, especially given its history of beating EPS estimates. However, the lack of revenue guidance raises concerns about the company's growth trajectory.

Bull Case

If Denali can demonstrate strong clinical trial results and better-than-expected revenue growth, it could lead to a significant positive reaction from investors.

Bear Case

Conversely, if the earnings report reveals continued losses without clear paths to profitability or updates on key trials, the stock may face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on Denali's clinical trials?

Investors will closely watch for any news that could impact the future success of Denali's therapies, which are crucial for its growth.

How does Denali plan to address its ongoing losses?

Understanding the company's strategy for achieving profitability will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of Denali's upcoming clinical trial results, which could significantly alter growth projections.

Supporting Evidence

Denali has a history of beating EPS estimates, which could lead to a positive surprise this quarter.

Options pricing indicates a much larger move than historical averages, suggesting that the market is not fully accounting for potential positive outcomes.

Key Risk

If clinical trial updates show promising results, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Denali's ability to turn its promising research into profitable products, and the upcoming earnings report will be pivotal.

Bull Confirmed If

Demonstrating a clear path to profitability with a substantial reduction in losses or positive revenue growth.

Bear Confirmed If

Continued losses without a clear strategy for improvement or disappointing clinical trial results.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a large potential move, indicating high uncertainty or anticipation surrounding the earnings report.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations and raises guidance, history suggests the stock could see an average one-day move of +4.52%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

Should the company miss expectations, history suggests a potential average one-day decline of -2.88%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on ongoing clinical trials and their expected timelines.
2Any commentary on strategies to reduce losses and improve profitability.
3Insights into market demand for Denali's therapies.
4Management's outlook on competitive positioning in the biotechnology sector.
5Details on any partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Denali Therapeutics Inc. (DNLI) is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth will indicate the demand for Denali's products and its market position.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1 2026, Denali reported an EPS of -$0.69, slightly beating expectations. However, the stock fell 3.43% the following day, indicating market disappointment despite the beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Denali can demonstrate strong clinical trial results and better-than-expected revenue growth, it could lead to a significant positive reaction from investors.

Bear Case

Conversely, if the earnings report reveals continued losses without clear paths to profitability or updates on key trials, the stock may face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on Denali's clinical trials?

Investors will closely watch for any news that could impact the future success of Denali's therapies, which are crucial for its growth.

How does Denali plan to address its ongoing losses?

Understanding the company's strategy for achieving profitability will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of Denali's upcoming clinical trial results, which could significantly alter growth projections.

Supporting Evidence

Denali has a history of beating EPS estimates, which could lead to a positive surprise this quarter.

Options pricing indicates a much larger move than historical averages, suggesting that the market is not fully accounting for potential positive outcomes.

Key Risk

If clinical trial updates show promising results, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Denali's ability to turn its promising research into profitable products, and the upcoming earnings report will be pivotal.

Bull Confirmed If

Demonstrating a clear path to profitability with a substantial reduction in losses or positive revenue growth.

Bear Confirmed If

Continued losses without a clear strategy for improvement or disappointing clinical trial results.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a large potential move, indicating high uncertainty or anticipation surrounding the earnings report.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations and raises guidance, history suggests the stock could see an average one-day move of +4.52%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

Should the company miss expectations, history suggests a potential average one-day decline of -2.88%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on ongoing clinical trials and their expected timelines.
2Any commentary on strategies to reduce losses and improve profitability.
3Insights into market demand for Denali's therapies.
4Management's outlook on competitive positioning in the biotechnology sector.
5Details on any partnerships or collaborations that could enhance growth.